Nadia Cohen, PhD, joined CARB-X (a global non-profit partnership to combat antimicrobial resistance) in 2018 to help manage, support and oversee the scientific progress of a diverse portfolio of novel antibacterial vaccine and antibiotic projects targeting prevention and therapy of Neisseria gonorrhea, Klebsiella pneumonia, Pseudomonas aeruginosa, Staphylococcus aureus, Group A Streptococcus and other pathogens for which antimicrobial resistance is a threat. Prior to CARB-X, Nadia was a Senior Scientist at Moderna therapeutics, where she initiated and lead a bacterial vaccine discovery program using Moderna’s innovative mRNA platform. Nadia holds a Bsc in Biology (Hons) from Imperial College, received her PhD in Immunology from Harvard Medical School and completed her post-doctoral training in Microbiology at the Wyss Institute for Biological Engineering in Boston.